Google DeepMind releases AlphaGenome 2 to predict mutation effects in specific cells
Prepared by Sintelligent with the help of SI. Published in SI: . Updated: .
Researchers can now find mutations that act only in specific cells more quickly and choose disease experiments more precisely.
AlphaGenome 2 takes a DNA sequence of up to one million letters together with a description of a cell type or state and predicts gene expression, histone modifications, chromatin accessibility and DNA methylation. The model was trained on more than 107 million individual human and mouse cell profiles across 68 tissues. Unlike the first version, which averaged measurements across tissues, it can work with new cellular states without fine-tuning and reconstruct missing measurements. According to DeepMind, on the TenK10K dataset the model identified 30% of causal variants versus 16% for the fine-tuned first version, and determined the direction of gene effects in 43% of cases versus 23%. In a test, it reproduced a known mechanism of inflammatory bowel disease: a variant increases ETS2 gene activity specifically in gut macrophages. AlphaGenome 2 is available for non-commercial research through the API, with commercial access in private preview. It is a research tool, not an approved clinical or diagnostic system.
Sources 2